Research Article
Analysis of Motor Complication and Relative Factors in a Cohort of Chinese Patients with Parkinson’s Disease
Table 2
Characteristics of PD patients with or without motor fluctuations.
| | Motor fluctuations | With (n = 52) | Without (n = 114) | t/χ2 | value |
| | Sex (male/female) | 29/23 | 60/54 | 0.141 | 0.707 | | Age (mean ± SD, y) | 63.55 ± 9.30 | 66.92 ± 8.86 | 2.215 | 0.029 | | Onset age (mean ± SD, y) | 55.33 ± 9.81 | 63.41 ± 8.93 | 5.232 | <0.001 | | Disease duration (median, quartile, y) | 7 (5∼11) | 3 (2∼5) | 7.293 | <0.001 | | Clinical phenotypes (n, %) | | | 6.991 | 0.008 | | Tremor | 20 (38.46) | 69 (60.52) | | | | Bradykinesia-rigidity | 32 (61.54) | 45 (39.47) | | | | Modified Hoehn–Yahr stages (median, quartile) | 2.5 (2∼3) | 2 (1.5∼2.5) | 4.770 | <0.001 | | UPDRS III scores (mean ± SD) | 25.71 ± 13.93 | 20.59 ± 10.43 | 2.358 | 0.021 | | Daily levodopa dosage (mg, median, quartile) | 500 (375∼750) | 375 (375∼425) | 3.353 | 0.001 | | LEDD (mg/d, mean ± SD) | 670.07 ± 411.89 | 356.06 ± 329.37 | 6.475 | <0.001 | | L-dopa duration (mean ± SD, y) | 6.06 ± 3.98 | 1.52 ± 2.46 | 6.825 | <0.001 | | Medications (n, %) | | | | | | Levodopa-benserazide | 50 (96.15) | 85 (74.56) | 10.963 | 0.001 | | Levodopa-carbidopa | 8 (15.38) | 3 (2.63) | 9.387 | 0.002 | | Dopamine agonist | 38 (73.08) | 54 (47.37) | 9.553 | 0.002 | | MAO-B inhibitor | 17 (32.69) | 27 (23.68) | 1.488 | 0.223 | | COMT inhibitor | 9 (17.31) | 0 (0.00) | 20.862 | <0.001 | | Anticholinergic | 7 (13.46) | 19 (16.67) | 0.278 | 0.598 | | Amantadine | 9 (17.31) | 7 (6.14) | 5.113 | 0.024 |
|
|
Abbreviations: SD, standard deviation; UPDRS: unified Parkinson disease rating scale; LEDD: levodopa equivalent daily dose; Mao: monoamine oxidase; and COMT: catechol-o-methyltransferase.
|
